Lv2
120 积分 2024-04-09 加入
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
1个月前
已完结
A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
1个月前
已完结
Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis
1个月前
已完结
MM-711: Safety Outcomes Following Frontline Daratumumab-Based Therapy in Multiple Myeloma: A Systematic Reviewand Meta-Analysis
2个月前
已关闭
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects
2个月前
已完结
Bevacizumab: A Review of Its Use in Advanced Cancer
3个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
3个月前
已完结
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
3个月前
已完结
An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors
3个月前
已完结
A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers
3个月前
已完结
皖公网安备34019202002308
